Alkem Laboratories has officially announced the launch of semaglutide injection in India under three brand names - Semasize, Obesema, and Hepaglide. The pharmaceutical company received approval from the Drug Controller General of India (DCGI) for manufacturing and marketing semaglutide for type 2 diabetes mellitus and chronic weight management, priced at INR 450 per weekly treatment.

Product Launch and Regulatory Approval

The company has launched semaglutide as a subcutaneous injection administered once weekly, following successful Phase 3 clinical trials conducted in India. The DCGI approval covers the use of semaglutide for type 2 diabetes mellitus and chronic weight management as an adjunct to diet and exercise under appropriate medical supervision.

Product Options and Pricing Strategy

Alkem offers the semaglutide injection in a pre-filled disposable injection pen containing four doses for a month at INR 1,800.00, translating to a weekly cost of INR 450.00. Additionally, the company provides a reusable injection pen option for higher maintenance doses, allowing patients to replace only the medication cartridge rather than purchasing new disposable pens, thereby reducing costs and improving treatment adherence.

Market Access and Distribution

Dr. Vikas Gupta, Chief Executive Officer of Alkem, emphasized the company's commitment to making therapeutic advancements accessible through affordable pricing. The launch aims to lower barriers to treatment initiation and expand access to semaglutide therapy across India through Alkem's established distribution network and patient-friendly delivery devices.

The competitive pricing strategy positions Alkem's semaglutide as an accessible treatment option in the Indian diabetes and weight management market, potentially enabling healthcare practitioners to offer this therapy to a broader patient population.

Alkem Laboratories Limited has announced a scheduled virtual meeting with institutional investor Millennium Capital Management, set to take place on March 26, 2026. The pharmaceutical company disclosed this information to stock exchanges as part of its regulatory obligations under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Meeting Details

The company has provided specific details about the upcoming investor engagement:

Regulatory Compliance

Alkem Laboratories communicated this information to both major Indian stock exchanges - BSE Limited and the National Stock Exchange of India Limited. The company emphasized that this disclosure aligns with the relevant provisions of SEBI's listing regulations, which mandate transparency in investor communications.

Schedule Flexibility

The pharmaceutical company has indicated that the meeting schedule remains subject to potential changes. According to the official communication, any modifications could occur due to exigencies on the part of either the investor or the company. This standard disclaimer provides flexibility for both parties to adjust timing if operational requirements necessitate changes.

Corporate Communication

The disclosure was signed by Manish Narang, who serves as President – Legal, Company Secretary & Compliance Officer at Alkem Laboratories. The document was digitally signed and dated March 20, 2026, demonstrating the company's commitment to timely regulatory reporting and maintaining transparency with stakeholders regarding investor engagement activities.